Newly Independent Radiation Oncology Company Emerges as Industry Leader
with Distinct Focus on Partnership, Innovation and Integration
VEENENDAAL, The Netherlands, Sept. 13 /PRNewswire/ -- Nucletron announced today the successful management buy-out from Delft Instruments, creating an independent company fully dedicated to radiation oncology. Since its inception in 1974, Nucletron has operated several entities in the field of radiation oncology throughout the world. The consolidation of the various entities into one, focused company further establishes Nucletron in a leadership role in this rapidly changing field. Collaborative partnerships, pioneering research and development of advanced technological innovations will enable Nucletron to more effectively deliver cancer treatment solutions globally and set the company apart within the industry.
"The creation of an independent Nucletron is the result of the company's success in the past two years," said David Imperiali, chief executive officer of Nucletron. "Nucletron has a strong tradition of innovation in radiotherapy, and the breadth of our capability positions the company well to continue to make significant contributions to the treatment of cancer."
The previous company, under Delft Instruments, was created in 1994 by merging Nucletron, the global leader in brachytherapy solutions, with the Oldelft Simulix(TM) brand of radiation therapy simulation and imaging technology. Additionally, in 2003, Nucletron integrated the Helax and Theratronics treatment planning and management solutions, from MDS Nordion, into its portfolio to create Oncentra(R) MasterPlan(TM) and Oncentra(R) Information Management.
"Nucletron's ability to restructure itself, anticipate needs, and
incorporate new state-of-the-art products and services into our solutions
suite gives us the ability to create strong and long-lasting relationships
with our customers and partners," said Jeroen Cammeraat, chief opera
Copyright©2007 PR Newswire.
All rights reserved